{"title":"柳叶刀神经杂志2024；23日:1013 - 24","authors":"","doi":"10.1016/s1474-4422(25)00108-5","DOIUrl":null,"url":null,"abstract":"<em>Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.</em> Lancet Neurol <em>2024;</em> 23: <em>1013–24</em>—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3, the first footnote of table 1, and the indentation of “Atypical CIDP” row of table 1, and the appendix has also been corrected. These corrections have been made to the online version as of March 25, 2025.","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"57 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Neurol 2024; 23: 1013–24\",\"authors\":\"\",\"doi\":\"10.1016/s1474-4422(25)00108-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.</em> Lancet Neurol <em>2024;</em> 23: <em>1013–24</em>—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3, the first footnote of table 1, and the indentation of “Atypical CIDP” row of table 1, and the appendix has also been corrected. These corrections have been made to the online version as of March 25, 2025.\",\"PeriodicalId\":22676,\"journal\":{\"name\":\"The Lancet Neurology\",\"volume\":\"57 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1474-4422(25)00108-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1474-4422(25)00108-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2024; 23: 1013–24—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3, the first footnote of table 1, and the indentation of “Atypical CIDP” row of table 1, and the appendix has also been corrected. These corrections have been made to the online version as of March 25, 2025.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
